The Skin as a Window to the Central Nervous System in Frontotempolar Lombar Degeneration
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Skin biopsy.
- Who it may be relevant to
- Registry conditions: Frontotemporal Lobar Degeneration. Basic parameters: 50 years — 75 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- France
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
Frontotemporal lobar degeneration (FTLD) is a clinically heterogeneous syndrome, characterized by progressive decline in behaviour and/or language. From a pathological standpoint, like the great majority of neurodegenerative disorders, FTLD are proteinopathies, which are characterized by the presence of specific protein deposits in the Central Nervous System (CNS). Accordingly, the two main deposits observed in FTLD are either made of Tau or transactive response DNA binding protein 43 (TDP-43). In pathological conditions such as FTLD, both proteins are aggregated and hyperphosphorylated. It is now well established that the pathological process in some proteinopathies such as synucleinopathies (of which Parkinson's disease is the main representative) is not limited to the brain but also widespread throughout the peripheral autonomic networks, including the autonomic innervation of the skin. In this context, many independent studies have shown that the pathological process in PD could be detected using routine punch skin biopsies opening the way for the development of original histopathological markers of the disease. Our hypothesis is that such a scenario could also occur in FTLDs and that the detection of the pathological tau or TDP-43 protein in the skin could help in diagnosing FTLD. This is especially relevant as, despite the recent progress in genetics, neurobiology and neuroimaging, there are no available biomarkers for FTLD.
Detailed description
Participant with Frontotemporal Lobar degeneration equally distributed into behavioral variant of frontotemporal dementia (bvFTD), language variant with primary progressive aphasia (PPA) and motor presentations with atypical parkinsonian disorders (corticobasal degeneration-CBD and progressive supranuclear palsy-PSP) and motoneuron disorder (amyotrophic lateral sclerosis -ALS) will be included at Nantes University Hospital during a period of 24 months.
Healthy volunteers will be included as comparative group. A skin biopsy and venous blood samples will be collected for all participants.
Interventions
- Procedure Skin biopsy
A single 3 mm-diameter punch skin biopsy will be obtained from FTLD patients and healthy volunteers at the C8 paravertebral under local anesthesia to analyze cutaneous innervation
Primary outcome measures
- Amount of TDP 43 [Time frame: Day of inclusion]
- Amount of Tau assessed by Western blot and qPCR [Time frame: Day of inclusion]
Secondary outcome measures (5)
- Amount of Tau phosphorylation [Time frame: Day of inclusion]
- Amount of TDP 43 phosphorylation [Time frame: Day of inclusion]
- Neuropsychological characterization [Time frame: day of inclusion for patients vFTD, PPA and corticobasal degeneration-CBD and progressive supranuclear palsy-PSP within 12 months of inclusion for patients ALS]
- Behaviour profile [Time frame: day of inclusion for patients vFTD, PPA and corticobasal degeneration-CBD and progressive supranuclear palsy-PSP within 12 months of inclusion for patients ALS]
- FTLD mutation [Time frame: before inclusion]
Eligibility criteria
Inclusion Criteria (patients):
- Adressed or followed at memory clinic or ALS expert center at Nantes university hospital.
- Aged 50-75 years
- Fulfilling current diagnosis criteria for one of the disorder: vcfFTD, non-Alzheimer PPA (semantic or non fluent), DCB or PSP,ALS
- MMSE ≥ 18
- Membership of social security scheme
Inclusion Criteria (healthy volunteers):
- No history of neurological disease, diabetes, or alteration/damage of peripheral nervous system
- Aged 50-75 years Paired to at least one patient on age (less or more 5 years)
- MOCA ≥ 26
- Membership of social security scheme
Non inclusion Criteria (Patients and healthy volunteers):
- Concomitting conditions affecting the peripheral nervous system such as but not limited to diabetes, renal failure, thyroid disorder, vitamin B12 deficiency, acute and chronic inflammatory diseases HIV, syphilis
- Know allergy to local anesthetic
- Known coagulopathy
- Pregnant women or breastfeeding women
- Person under court protection sous sauvegarde de justice
- Person under guardianship
- Inability to sign an informed consent
Non inclusion criteria (Patients) • Patient with neurological disease other than FTLD
Non inclusion criteria (Healthy volunteers) :
- Evidence of neurological disorder at the inclusion including but not limted to FTLD, Parkinson disease, Alzheimer disease, lewy body dementia, Huntington disease, systemic lupus erythematosus multiple sclerosis; learning disabilities, mental retardation, severe hypoxic brain injuries, brain trauma with permanent cognitive impairments.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Allocation
- N/A
- Model
- Single group
- Masking
- Open label
- Primary purpose
- Other
Study locations
France · 1 center
- Nantes University Hospital — Nantes
Identifiers
NCT: NCT06490822 · RC23_0575